[go: up one dir, main page]

SK284877B6 - Zlúčeniny a ich použitie na liečbu zápalovej odpovede - Google Patents

Zlúčeniny a ich použitie na liečbu zápalovej odpovede Download PDF

Info

Publication number
SK284877B6
SK284877B6 SK1097-2001A SK10972001A SK284877B6 SK 284877 B6 SK284877 B6 SK 284877B6 SK 10972001 A SK10972001 A SK 10972001A SK 284877 B6 SK284877 B6 SK 284877B6
Authority
SK
Slovakia
Prior art keywords
compound
alkyl
inflammatory response
amino
caused
Prior art date
Application number
SK1097-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK10972001A3 (sk
Inventor
Joel M. Linden
Gail W. Sullivan
Ian J. Sarembock
Timothy Macdonald
Mark Okusa
Irving L. Kron
W. Michael Scheld
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Publication of SK10972001A3 publication Critical patent/SK10972001A3/sk
Publication of SK284877B6 publication Critical patent/SK284877B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1097-2001A 1999-02-01 2000-01-31 Zlúčeniny a ich použitie na liečbu zápalovej odpovede SK284877B6 (sk)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30
PCT/US2000/002324 WO2000044763A2 (fr) 1999-02-01 2000-01-31 Compositions permettant de traiter une reponse inflammatoire

Publications (2)

Publication Number Publication Date
SK10972001A3 SK10972001A3 (sk) 2002-01-07
SK284877B6 true SK284877B6 (sk) 2006-01-05

Family

ID=27557920

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1097-2001A SK284877B6 (sk) 1999-02-01 2000-01-31 Zlúčeniny a ich použitie na liečbu zápalovej odpovede

Country Status (25)

Country Link
EP (1) EP1150991B1 (fr)
JP (1) JP4837831B2 (fr)
KR (1) KR100668006B1 (fr)
CN (1) CN1191266C (fr)
AR (1) AR029332A1 (fr)
AT (1) ATE263777T1 (fr)
AU (2) AU778870B2 (fr)
BR (1) BR0007864A (fr)
CA (1) CA2361614C (fr)
CZ (1) CZ296404B6 (fr)
DE (1) DE60009665T2 (fr)
DK (1) DK1150991T3 (fr)
EE (1) EE05185B1 (fr)
ES (1) ES2215609T3 (fr)
HU (1) HU228937B1 (fr)
IL (2) IL144188A0 (fr)
MX (1) MXPA01007850A (fr)
MY (1) MY129445A (fr)
NO (1) NO321216B1 (fr)
NZ (1) NZ513096A (fr)
PL (1) PL199953B1 (fr)
PT (1) PT1150991E (fr)
SK (1) SK284877B6 (fr)
UA (1) UA72912C2 (fr)
WO (1) WO2000044763A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
WO2005097140A2 (fr) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Antagonistes selectifs des recepteurs a2a de l'adenosine
WO2005107463A1 (fr) * 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonistes de recepteurs de l'adenosine a2a servant au traitement d'une nephropathie diabetique
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2576826C (fr) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a<sb>2a</sb>
WO2007120972A2 (fr) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Procede permettant de traiter l'anemie a hematies falciformes
WO2007107598A1 (fr) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Agonistes du récepteur a2a phosphorylé
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2009541438A (ja) * 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） 治療用化合物
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
DK2306971T3 (en) 2008-07-03 2015-05-11 Univ Virginia Patent Found The unit dosage of apadenoson
AU2010266313A1 (en) 2009-06-30 2012-01-19 Forest Laboratories Holdings Limited Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2A R agonists
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
EP3988560A4 (fr) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences Composé à petites molécules ayant un antagonisme du récepteur de l'adénosine a2a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
WO1990005526A1 (fr) * 1988-11-15 1990-05-31 Yamasa Shoyu Kabushiki Kaisha Agent de traitement et de prophylaxie des troubles ischemiques du c×ur ou du cerveau
DE69022176T2 (de) * 1989-06-20 1996-02-15 Toa Eiyo Ltd., Tokio/Tokyo Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
WO1991009864A1 (fr) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Medicament pour le traitement d'affections ischemiques du c×ur ou du cerveau
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
CA2295195C (fr) * 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
JP4837831B2 (ja) 2011-12-14
EP1150991B1 (fr) 2004-04-07
CZ20012781A3 (cs) 2002-01-16
KR20020013494A (ko) 2002-02-20
AU778870B2 (en) 2004-12-23
DE60009665T2 (de) 2004-08-19
CN1191266C (zh) 2005-03-02
ES2215609T3 (es) 2004-10-16
KR100668006B1 (ko) 2007-01-15
UA72912C2 (uk) 2005-05-16
HU228937B1 (en) 2013-06-28
SK10972001A3 (sk) 2002-01-07
CA2361614E (fr) 2000-08-03
AU2745400A (en) 2000-08-18
DE60009665D1 (de) 2004-05-13
HUP0200224A2 (en) 2002-06-29
AU2005201255A1 (en) 2005-04-21
WO2000044763A3 (fr) 2000-12-14
PL199953B1 (pl) 2008-11-28
EE200100397A (et) 2002-08-15
NO20013507D0 (no) 2001-07-13
CA2361614A1 (fr) 2000-08-03
NZ513096A (en) 2003-01-31
BR0007864A (pt) 2001-11-06
MXPA01007850A (es) 2002-08-20
IL144188A (en) 2008-12-29
CA2361614C (fr) 2008-08-26
NO20013507L (no) 2001-09-18
EP1150991A2 (fr) 2001-11-07
EE05185B1 (et) 2009-06-15
HUP0200224A3 (en) 2005-02-28
CZ296404B6 (cs) 2006-03-15
DK1150991T3 (da) 2004-06-07
AU2005201255B2 (en) 2008-02-28
PT1150991E (pt) 2004-08-31
HK1047288A1 (en) 2003-02-14
JP2002536300A (ja) 2002-10-29
IL144188A0 (en) 2002-05-23
WO2000044763A2 (fr) 2000-08-03
NO321216B1 (no) 2006-04-03
MY129445A (en) 2007-04-30
AR029332A1 (es) 2003-06-25
CN1357002A (zh) 2002-07-03
ATE263777T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
US6232297B1 (en) Methods and compositions for treating inflammatory response
SK284877B6 (sk) Zlúčeniny a ich použitie na liečbu zápalovej odpovede
JP4514452B2 (ja) Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
AU2002362443A1 (en) 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
MX2008014638A (es) Aril piperidin alquinil adenosinas sustituidas como agonistas a2ar.
RU2258071C2 (ru) Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
ZA200106243B (en) Compositions for treating inflammatory response.
HK1047288B (en) Compositions for treating inflammatory response

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20180131